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Ethical, Legal, and Social Issues of the Human
Genome Project: What to Do with What We Know
Since fisal year 1991, the U.S. Human
Genome Project has spent $170.6 million
in federal funds to help isolate genes associ-
ated with Huntington's disease, amy-
otrophic lateral sclerosis, neurofibromatosis
types 1 and 2, myotonic dystrophy, and
fragile X syndrome and to localize genes
that predispose people to breast cancer,
colon cancer, hypertension, diabetes, and
Alzheimer's disease. Now comes the hard
part.
Biology's 21st century megaproject
starts to look relatively manageable com-
pared to another challenge facing the enter-
prise: sorting out ethical, legal, and social
issues associated with using this informa-
tion. "The Human Genome Project," wrote
Senior Editor Barbara Jasny in the October
1 Science editorial, stretches "the limits of
the technology and the limits ofour ability
to ethically and rationally apply genetic
information to our lives."
Priorities
Concerned about potential misuse of
detailed genetic information, NIH in 1992
created the Ethical, Legal and Social Imp-
lications (ELSI) Branch of the project,
which receives 3% ofthe multimillion-dol-
lar genome budget. In the 1993 progress
report, Michael Gottesman, acting director
of NIH Intramural Research, introduces
the most urgent research, educational, and
policy issues, including developing consent
and confidentiality guidelines for research
with human subjects; determining a profes-
sional standard of care for delivering new
genetic services; developing uniform stan-
dards governing the privacy of organs,
blood, and tissues banked for clinical pur-
poses; protecting against employment and
insurance discrimination based on genetic
information; and improving public under-
standing of the potential and limits of
genetics to prevent overly deterministic
readings of genetic test results that expose
people to social stigma.
Researchers also will study the eugenics
movement and other social uses and misus-
es of genetic research, the likely priority of
new genetic services in the health care sys-
tem, the effects of commercialization on
genetic services and research, and sociologi-
cal implications of the genome project's
dynamics and priorities.
Lurking between the lines in this prior-
ity list are all the elements that constitute
what surely will be an extended debate, not
only about whether and how to use life's
ultimate database but, as David Heyd
writes in Genethics: Moral Issues in the
Creation ofPeople, about "tampering with
the natural biological process of species
evolution and individual evolution . . . a
form ofmetaphysical trespass."
ELSI
According to the 1991-1992 Progress
Report ofthe National Centerfor Human
Genome Research, ELSI aims to develop
programs addressed at understanding the
project's ethical, legal, and social implica-
tions and to define major issues and devel-
op policy to address them. Knowledge
gained through the genome project can be
used by scientists in many ways: to unravel
the pathogenesis of a disorder or under-
stand the expression of a normal human
trait, to develop clinical tests for disease or
trait-specific forms of the gene, and to
detect chemical-specific patterns ofgenetic
changes.
But the effects ofgetting and using this
knowledge create tough choices for nearly
everyone. The progress report elaborates:
* Individuals and families must decide
whether to participate in testing, with
whom to share the results, and how to
act on them.
* Health professionals must decide when
to offer testing, how to ensure its quali-
ty, how to interpret the results, and to
whom they disclose information.
* Employers, insurers, the courts, and
other social institutions must decide
the relative value of genetic informa-
tion in the decisions they make.
* Governments must decide how to reg-
ulate production and use of genetic
tests and the resulting information and
how to make testing and counseling
services accessible.
* Society must decide how to improve
public understanding ofscience and its
social implications and increase public
participation in science policy making.
Concerns
The presymptomatic DNA-based diagnosis
would seemingly eliminate much pain and
suffering. It also, according toJasny's Science
editorial, "poses a challenge to a society that
has not demonstrated a clear ability to eval-
uate risks and make reasoned choices."
Knowledge about whether someone has
a genetic tendency toward a disease could
invite social prejudices, a 1988 National
Academy of Sciences report said. Health
insurance companies could use genetic
information to reject people who might be
inherently risky investments, for example,
or employers could reject prospective
employees for similar reasons. In Nov-
ember, a committee of the Institute of
Medicine of the National Academy of
Sciences released a report outlining policy
guidelines and legislative recommendations
designed to "avoid involuntary and ineffec-
tive testing and to protect confidentiality."
The report, Assessing Genetic Risks: Impli-
cations for Health andSocialPolicy, identi-
fies concerns such as quality control mea-
sures, including federal oversight for test-
ing laboratories, and better genetics train-
ing for medical practitioners. It also rec-
ommends such measures as voluntary
screening and genetic counseling for cou-
ples in high-risk populations and urges
caution in using and interpreting presymp-
tomatic or predictive tests. Also needed,
according to the report, are increased pub-
lic education about genetics and a national
advisory committee to set genetic testing
standards.
Thomas Murray summarizes these and
other ethical concerns in "Ethical Issues in
Human Genome Research," from The
EthicalDimensions oftheBiologicalSciences.
"The most important movement in the
ethics of workplace genetic testing,"
Murray writes, "has been away from the
original vision of a public health measure
to screening as a way of reducing illness-
related costs with no effect on the overall
incidence ofdisease."
Employee illness in the United States
costs employers money. Growing health
insurance costs are prompting employers
to look for ways to reduce costs like health
insurance, disability insurance, lost pro-
ductivity, and training of replacement
workers for skilled positions. Increased
employer concerns about the costs of ill-
ness and the prospect of genetic tests that
reveal predispositions to disease, Murray
adds, "are fertile ground for the use ofsuch
tests to screen workers."
Other factors may prompt insurers to
use genetic tests. Once the tests become
available, people can be tested privately to
learn about their risks for disease. Those
who are at risk are likely to buy insurance
and in larger amounts. Competition among
insurance companies will drive companies
to genetic screening. A company that uses
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such tests would be able to give lower rates
to those with no genetic predisposition to
disease and higher rates to those at risk.
People offered lower rates are more likely to
buyinsurance from that company, and those
at risk will seek insurance from companies
that do no genetic testing. These companies
will either raise their rates to avoid bankrupt-
cyor begin usinggenetic tests.
These are a few of the social and legal
questions raised by the availability ofgenetic
testing. But there are medical/ethical ques-
tions as well: Is there is a need for a genome
program? Are both somatic and germline
therapy (somatic therapy corrects defects by
adding new genes to cells but does not pass
genetic changes to offspring; germline thera-
py passes genetic changes to future genera-
tions) medically and ethically acceptable for
therapeutic but not nontherapeutic purposes?
Is prenatal diagnosis ethically acceptable
except where parents use it strictly forgender
identification?
Limits to Benefits
While researchers work to have a complete
human sequence by 2005, Kenneth Olden,
director of the NIEHS, notes that human
disease depends on more than genetics.
"We've spent a lot of effort and financial
resources to understand the role ofgenetics
in human disease and dysfunction," he says,
"but a comparable effort has not been ex-
pended to understand how the environment
causes impaired human health." Environ-
mental contributions to disease, he adds, are
entirely preventable.
At Montreal's McGill University, Abby
Littman, a well-known critic ofthe genome
project, worries also about the limitations of
the project to solve environmental health
problems. "Everything that's been done so
far is about managing the genome project,"
she says, "instead of questioning the whole
issue ofwhether there should be a human
genome project."
Littman, a professor in McGill's De-
partment ofEpidemiology and Biostatistics,
chairs the Human Genetics Committee of
the Cambridge, Massachusetts-based Coun-
cil for Responsible Genetics, a nonprofit
genetics consciousness-raising group that
publishes Gene Watchnewsletter.
"Why are we so busy mapping the
genome? Why don't we map the environ-
ment instead of mapping the genome," she
adds, "and worry about things that really
make us sick that we don't know anything
about? Why do we think it's so much easier
to change genes than environmental condi-
tions that put us at risk? Because it's more
expensive to dean up the environment than
to deal with people who are at medical risk
because ofthe environment."
Littman contends that most human dis-
abilities happen after birth and are caused by
accidents, injuries, and other environmental
factors that in the long term might be harder
to control than genetic disorders. And she
believes the public deserves to be educated
and have a say in such matters. In terms of
genetic technology, "decisions are being
made and things are happening that need
publicairing," she says.
Although Littman agrees that genetic
therapycould help create a society where no
one is physically or mentally defective, she
urges scientists and the public to question
genetic goals. Says Littman, "Do wewant to
live in a society where nobody is born with
Down's syndrome? If so, why? That's an
ultimate aim ofthese tests. Does this make
us a better society? I'd like to make geneti-
cists think about these questions as they do
theirwork."
Therapeutic Genetics
H.J.J. Leenen, professor of social medicine
and health law at the University ofAm-
sterdam, draws another kind of line in the
sands of genetic controversy. In his article,
"Genetic Manipulation with Human Be-
ings," published in Biomedical Ethics,
Leenen distinguishes between therapeutic
and nontherapeutic genetic engineering. He
endorses therapeutic manipulation for
somatic cell and germline therapies, but
rejects the use of nontherapeutic genetic
engineering, which he calls dangerous and
unfair to future generations.
"There is a solid ethical and legal basis
for therapeutic measures," Leenen writes,
"and even for assumptions about the wishes
of a future generation. The elimination of
suffering and disease justifies decision-mak-
ing on its behalf." But the situation is differ-
ent, he believes, for eugenics (hereditary
improvement by genetic control) or genetic
enhancement. "The present generation
should avoid using genetic engineering to
impose its own ideas about personality,
intelligence, character traits, talents and the
likeon future generations," headds.
Prenatal Diagnosis and
Reproductive Choice
In his article, "Prenatal Diagnosis and the
Ethics ofUncertainty," in BiomedicalEthics;
Eric T. Juengst describes the moral uncer-
tainty of prenatal diagnosis as a medical
practice because prenatal diagnosis is associ-
atedwith selective abortion.
Juengst, acting chief of the ELSI Pro-
gram Branch at the National Center for
Human Genome Research, concludes that
prenatal diagnosis is a tool parents should
be able to use to make their own reproduc-
tive choices. But, he believes, access to such
technology should be denied parents who
seek prenatal diagnosis only for purposes of
gender identification.
"The moral framework that will guide
the practice of prenatal diagnosis as a
mature medical technology is still emerg-
ing," Juengst writes. "Its foundations are in
the ethical traditions of clinical medicine
and genetic counseling, with their comple-
mentary imperatives to enhance fetal welfare
and facilitate parental choice." Juengst con-
tinues, "As the next generation ofdiagnostic
techniques raises new moral, conceptual and
social uncertainties, the relationship be-
tween the traditions will be increasingly
important to the practice's moral stability."
There Ought to Be a Law
In terms ofNIH's ELSI program, Juengst is
fielding criticism aimed at the branch's fail-
ure to produce a federal genetic privacy law
and at the branch's unsuitability to act as its
own watchdog.
"Given what we know about the history
ofother attempts to develop and introduce
sweeping social legislation, . . ." Juengst
says, "it's not surprising that three years into
the effort we don't have a federal genetic
privacy law."
Such an effort, he adds, is roughly equal
in complexity to the human genome project
itself. The criticism is less about a specific
law than it is about "the sense that ELSI
ought to deliver some tangible products," he
says. "And the most visible kind ofproduct
is a law. Thereought to be a law."
Asked when it would be reasonable to
expect such a law, Juengst says he doesn't
know ifanyone "could predict the course of
a piece oflegislation like that." In the mean-
time, NIH's ELSI branch has delivered sev-
eral policy-type products (as listed in the
progress report) and has others in theworks.
On the watchdog issue, taken up in an
Office of Technology Assessment back-
ground paper released October 13, Bio-
medical Ethics in U.S. Public Policy-
Juengst says, "We don't feel the work we
sponsor is compromised by fact that we
sponsor it. Grantees are free to speak their
minds about the issues. On the other hand,"
headds, "it is a challenge to corral these aca-
demics into a policy-making forum. It's not
what NIH is set up to do."
Juengst said the OTA report, which
concluded that the United States should
have a federal bioethics body, is perceived in
the scientific policy and ethics community
as a first step in that effort. Juengst said he
"would breathe a sigh of relief' at the for-
mation of such a federal commission. For
the commission, as well as the public, the
challenge will be to manage the work that
comes out ofthe NIH genome project."
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